NEW YORK: An experimental Alzheimer’s drug being developed by a US biotech group has offered hope that scientists may be closer to a breakthrough for the devastating disease, after early trials showed the treatment slowed the rate of cognitive decline.
Biogen’s Aducanumab is one of several drugs under development by big pharmaceutical groups that aim to reduce so-called “amyloid plaque”, a sticky build up in the brain that many believe is responsible for Alzheimer’s.
A year-long study of 166 patients with a mild form of the disease showed that Biogen’s drug significantly reduced the build-up of plaque and delayed the onset of cognitive decline…